A study utilizing data from 7,463 pancreatic neuroendocrine tumor (PanET) patients developed a gradient boosting machine (GBM) model, marking it as the most effective tool for predicting liver metastasis. The model achieved an AUC of 0.937 and an accuracy of 0.87, highlighting independent risk factors like T-stage, N-stage, and previous treatments. It culminated in a […]
Category: Sarcoma & rare tumors
Endoscopic resection proves effective for certain esophageal tumors
The study identifies significant clinicopathological differences between esophageal gastrointestinal stromal tumors (e-gist) and gastric gastrointestinal stromal tumors (g-gist), noting e-gist’s stronger male predominance, older median age, and increased tumor size and ulceration. Remarkably, endoscopic resection (ER) is found to be comparably effective to surgical resection for selected e-gist patients (tumors ≤5 cm without ulceration), with […]
Incomplete resections lead to high rates of residual tumors
A significant 48.4% of patients undergoing salvage local resection (SLR) for incompletely resected rectal neuroendocrine tumors (r-NETs) had residual tumors. Rates varied by resection method: 70% for cold forceps polypectomy, 41.7% for conventional polypectomy/endoscopic mucosal resection, and 0% for modified techniques. Multivariate analysis indicated that suspected remnant tumors and the use of cold forceps were […]
AI Model Outperforms Clinicians in Tumor Differentiation
An artificial intelligence model employing endoscopic ultrasonography (EUS) has demonstrated effective differentiation between small gastric stromal tumors (GSTs) and gastric leiomyomas (GLs). Utilizing a dataset of 358 EUS images, the ResNet50 architecture achieved impressive area under the curve (AUC) values of 0.994 and 0.911 for micro and small tumors respectively. In comparison, clinicians and clinical […]
Distinct prognostic implications observed in pancreatic neuroendocrine neoplasms
Findings indicate significant differences between insulinomas and non-functional pancreatic neuroendocrine neoplasms (nf-pnens) regarding prognosis and tumor biology. nf-pnens exhibited higher rates of lymph node involvement, perineural invasion, and more advanced tumor grades. The study’s multivariate analysis revealed that nf-pnens with lymph node metastasis and high grading correlated with reduced recurrence-free survival. Genetically, distinct somatic mutations […]
Pancreatic neuroendocrine tumor resections lead to poorer outcomes
Observational data indicate that pancreatic resections for neuroendocrine tumors (pnet) result in a significantly lower rate of ideal outcomes compared to pancreatic ductal adenocarcinoma (pdac) patients. The ideal outcome rate was 47.7% for pnet versus 55.7% for pdac, primarily due to a fourfold increase in postoperative pancreatic fistulas after pancreatoduodenectomy for pnet. This difference emphasizes […]
Favorable long-term outcomes observed in gastric neuroendocrine tumors
A study analyzing 69 patients with gastric neuroendocrine tumors (GNETs) showed a favorable prognosis, with 5-year survival rates at 93.8% and recurrence rates at 7.25%. Most tumors were grade 1 and type I, with treatment variations between tumor grades; grade 1 patients often opted for endoscopic treatment, while grade 2 received surgical or chemotherapeutic interventions. […]
Fluorescence imaging effectively locates small pancreatic tumors.
Fluorescence imaging using indocyanine green has shown promising results for the intraoperative localization of small pancreatic neuroendocrine tumors. In a case report involving five patients, successful tumor identification and laparoscopic partial resections were achieved without serious complications. Pathological reviews confirmed four neuroendocrine tumors of G1 stage and one case of neuroendocrine cell hyperplasia. The findings […]
PRRT enhances survival in patients after GEP-NET progression
Peptide receptor radionuclide therapy (PRRT) significantly improves progression-free survival (PFS) and overall survival (OS) in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who progress after surgical resection. Among 237 analyzed patients, those receiving PRRT experienced a median PFS of 32.4 months compared to 11.0 months for those who did not (p < 0.001). Median OS […]
Endoscopic ultrasonography-guided ethanol injections demonstrate efficacy for small pancreatic tumors
A prospective multicenter study evaluated endoscopic ultrasonography-guided ethanol injections (EUS-EI) for treating small pancreatic neuroendocrine neoplasms (PNENs). Of the 25 patients treated, 76% achieved the primary endpoint compared to surgical outcomes, and 88% attained complete ablation at 1 and 6 months. Safety results were promising, with 96% experiencing no severe adverse events within one month. […]